FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 337:365-372 August 7, 1997 Number 6 Next

Abstract PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Oxidizing metabolites generated at the site of coronary angioplasty can induce chain reactions that may lead to restenosis. Antioxidants may counter oxidative stress and modify neointimal formation and vascular remodeling. Experimental data and small clinical studies have suggested that antioxidants may prevent restenosis after angioplasty. In a double-blind, randomized trial, we studied whether drugs with antioxidant properties decrease the incidence and severity of restenosis after angioplasty.

Methods One month before angioplasty, 317 patients were randomly assigned to receive one of four treatments: placebo, probucol (500 mg), multivitamins (30,000 IU of beta carotene, 500 mg of vitamin C, and 700 IU of vitamin E), or both probucol and multivitamins — all given twice daily. Patients were treated for four weeks before and six months after angioplasty. Patients received an extra 1000 mg of probucol, 2000 IU of vitamin E, both probucol and vitamin E, or placebo 12 hours before angioplasty, according to their treatment assignments. Base-line and follow-up angiograms were interpreted by blinded investigators using a quantitative approach.

Results The mean (±SD) reduction in luminal diameter six months after angioplasty was 0.12±0.41 mm in the probucol group, 0.22±0.46 mm in the combined-treatment group, 0.33±0.51 mm in the multivitamin group, and 0.38±0.50 mm in the placebo group (P = 0.006 for those receiving vs. those not receiving probucol, and P = 0.70 for those receiving vs. those not receiving vitamins). Restenosis rates per segment were 20.7 percent in the probucol group, 28.9 percent in the combined-treatment group, 40.3 percent in the multivitamin group, and 38.9 percent in the placebo group (P = 0.003 for probucol vs. no probucol). The rates of repeated angioplasty were 11.2 percent, 16.2 percent, 24.4 percent, and 26.6 percent, respectively (P = 0.009 for probucol vs. no probucol).

Conclusions The antioxidant probucol is effective in reducing the rate of restenosis after balloon coronary angioplasty.

Methods

Study Design and Study Population

The MVP study was a double-blind, placebo-controlled, randomized trial with four study groups. The protocol was approved by the institutional review board at the Montreal Heart Institute. Patients referred for elective coronary angioplasty were evaluated at least 30 days before the scheduled procedure. Eligible patients were asked to participate and to provide written informed consent. Preliminary evaluation included a medical history taking and physical examination, electrocardiography, blood count, and blood chemistry tests including measurements of serum lipids and glucose and liver, kidney, and thyroid function. Patients were eligible if they were scheduled to undergo standard balloon angioplasty on at least one native coronary artery and had at least one target lesion with stenosis of 50 percent or more of the luminal diameter as measured by calipers on the angiogram. We excluded subjects unable to participate in the pretreatment evaluation or unable to return for follow-up; those who had had a myocardial infarction within the previous seven days; patients scheduled to undergo stenting or atherectomy; those who had undergone angioplasty for another lesion in the preceding six months or who were being treated for a restenotic lesion; and patients undergoing angioplasty of a bypass graft or of a bypassed native vessel with a patent graft.

Randomization and Drug Regimen

Beginning 30 days before the scheduled angioplasty, patients were randomly assigned to receive one of four treatments: probucol alone, multivitamins alone, the combination of probucol and multivitamins, or placebo. Two tablets of the multivitamin complex, each of which contained 15,000 IU of beta carotene, 250 mg of vitamin C, and 350 IU of vitamin E (dl-alpha-tocopherol), or the matched placebo were administered twice daily. Probucol (two 250-mg tablets; Lorelco, Merrell, Kansas City, Mo.) or matched placebo was also administered twice daily. All patients received an extra dose of 2000 IU of vitamin E, 1000 mg of probucol, both vitamin E and probucol, or placebo 12 hours before angioplasty, according to their random treatment assignments. All patients in whom angioplasty was successful and who did not have procedure-related cardiac complications continued to receive the assigned study treatment until follow-up angiography was performed.

Angioplasty Procedure and Angiographic Methods

All patients received aspirin (325 mg daily) for the entire study period. Balloon angioplasty was performed according to standard techniques. Control angiography both before and after angioplasty and at follow-up was preceded by the administration of intracoronary nitroglycerin (0.3 mg). The sequence of contrast injections with the exact degree of angulation was recorded for angiography performed before the procedure, immediately after the final balloon inflation, 15 minutes later, and at follow-up. Electrocardiograms were obtained before angioplasty, immediately thereafter, and daily until discharge. Creatine kinase and creatine kinase MB fraction were measured on the evening after the procedure and the following morning.

Patients were excluded from the study if the stenosed coronary-artery segment could not be dilated; if initially successful angioplasty was followed by persistent abrupt closure; if a Q-wave infarction occurred in the territory of the dilated artery; if angioplasty was unsuccessful, necessitating emergency revascularization; or if the results of angioplasty were suboptimal and a stent was implanted.

Follow-Up Evaluation

Patients who underwent successful angioplasty were discharged with one month's supply of the study medication, aspirin, and any other drugs judged necessary. They were specifically asked not to take additional vitamins. Patients returned at one, three, and six months for a new supply of drugs; at this time, pill counts and a clinical evaluation were performed. Patients were assessed for ischemic symptoms and for any symptoms, whether or not they were related to the study medication or the angioplasty procedure. Compliance was further evaluated by measurements of drug levels in serum at each visit. These levels were not made available to investigators during the trial, in order to maintain blinding. Blood-chemistry values assessed at base line were measured again at discharge and at each follow-up visit. The one-month and six-month visits included treadmill exercise tests. Patients were readmitted for follow-up coronary angiography five to seven months after angioplasty. Those in whom arteriography was performed for clinical reasons before the fifth month returned for another angiographic examination at five to seven months if there was no definite arteriographic evidence of restenosis in one or more dilated segments.

Assessment of Diet and Dietary Intervention

Each patient had four complete food-intake evaluations; the modified Burke questionnaire¹¹ was used at base line and a food journal at other visits, with questions to assess the intake of fruit, vegetables, and dietary supplements. Food composition was determined according to the Canadian Nutrient File.¹² Patients were given specific dietary counseling at each visit. The American Heart Association Step 1 diet¹³ was taught to all patients. Specific attention was given to vitamins and minerals usually consumed. Daily dietary intake of vitamins E and C and beta carotene was limited, and patients were instructed to avoid vitamin and mineral supplements. The diet met 1990 Canadian standards for all nutrients.¹⁴

Measurement of Drug Levels

The levels of probucol and alpha-tocopherol in serum were determined by isocratic reverse-phase high-performance liquid chromatography.¹⁵ All samples were frozen at -70°C and analyzed in duplicate.

Quantitative Coronary Angiography

The four coronary arteriograms (obtained before the procedure, immediately after the procedure, 15 minutes after the procedure, and at the final follow-up visit) were analyzed together by experienced technicians supervised by a cardiovascular radiologist who was blinded to the patients' treatment assignments, using the Coronary Measurement System (Medis, Nuenen, the Netherlands).¹⁶ Measurements were made in a single projection, showing the most severe stenosis. The projection that showed the arterial segment with good opacification, as nearly perpendicular to the x-ray beam as possible, was selected for analysis. Whenever possible, the same projection was used in all four arteriograms to allow more accurate comparison. The variation among repeated measurements of the percentage of stenosis in our laboratory is 8.6 percent when frames recorded one to six months apart are analyzed.¹⁷ A change of 15 percent, or roughly 2 SD of the mean variation, was taken to indicate a clinically important change.

Definitions and End Points

Restenosis was evaluated in terms of both numbers of patients and numbers of dilated coronary-artery segments. All measurements were made by quantitative angiographic methods. Only patients in whom at least one lesion was successfully dilated were included in the analysis of restenosis. Successful dilation was defined as residual stenosis of less than 50 percent of the luminal diameter (as measured 15 minutes after the procedure), with improvement of at least 15 percent in luminal diameter as compared with the measurement before the procedure. The angiogram obtained 15 minutes after angioplasty was used in the analysis of outcomes in order to exclude the effects of early elastic recoil, at least in part, from the assessment of restenosis.

The primary end point with respect to efficacy was the extent of restenosis, defined as the reduction in the minimal luminal diameter from the angiogram obtained 15 minutes after angioplasty to that obtained at follow-up. In patients who were undergoing angioplasty on more than one lesion, the means of the luminal diameters for all successfully dilated sites 15 minutes after angioplasty and at follow-up were computed. Restenosis was also defined as a dichotomous outcome variable and analyzed in terms of the change in the percentage of stenosis. A patient was defined as having restenosis if at least one dilated segment had stenosis of 50 percent or more of the luminal diameter at follow-up, with an increase of 15 percent or more in the degree of stenosis from that measured on the angiogram obtained 15 minutes after angioplasty. Only successfully dilated segments were considered in the evaluation of the proportion of segments with restenosis. Major secondary clinical end points were death, myocardial infarction, coronary bypass surgery, and repeated angioplasty.

Statistical Analysis

A previous study at our institution had shown a mean (±SD) reduction of 0.38±0.44 mm in luminal diameter six months after angioplasty.¹⁸ We calculated that a total of 364 patients were needed for us to be able to detect a 40 percent reduction in luminal loss during the six months after angioplasty, with a power of 0.90 and a two-tailed significance level of 0.05. Assuming a dropout rate of 10 percent and a 90 percent rate of compliance with the protocol, we increased the target sample size by roughly 20 percent to 440 patients.

For the patients who completed the trial without protocol violations (criteria included taking more than 80 percent of the assigned study medications), the primary end point with respect to efficacy — the extent of restenosis — was evaluated with two-way analysis of covariance with control for the luminal diameter 15 minutes after angioplasty and for the distribution of target vessels. In the intention-to-treat analysis, which included all randomized patients with successful angioplasty, the dichotomous outcome (restenosis or no restenosis) was analyzed similarly by multiple logistic regression. All patients who withdrew early were considered to have restenosis for purposes of the intention-to-treat analysis. Patients who completed the trial with protocol violations were considered to have restenosis or no restenosis depending on the measurements obtained at the final angiography.

The proportion of dilated segments with restenosis was analyzed by the generalized-estimating-equations technique,¹⁹ which takes into account potential interdependence among multiple segments in the same patient. All secondary end points were analyzed in a way similar to that used for the primary efficacy end point. Depending on the outcome, analysis of covariance or multiple logistic regression was used. The proportions of patients reporting adverse effects of treatment were compared with use of chi-square tests. An interim statistical analysis, based on the Pocock constant-boundary approach,²⁰ was scheduled after the first 200 patients completed follow-up (significance levels of 0.0294 were used for both interim and final analyses in order to maintain an overall significance level of 0.05).

Results

A total of 317 patients had entered the trial when the interim analysis was performed on data for the first 200 patients. The results showed that probucol had a significant effect on the primary efficacy end point (P = 0.018). The study was therefore stopped when the additional 117 patients completed follow-up.

During the study, 1179 patients were screened, of whom 862 were excluded. Patients were distributed in the four groups as follows: 80 received probucol alone, 78 multivitamins alone, 80 probucol plus multivitamins, and 79 placebo. Selected demographic, clinical, and angiographic characteristics of the groups are shown in Table 1. The only significant differences at base line were in sex and the distribution of target vessels; there were more women in the combined-treatment group, and a greater number of patients were scheduled for dilation of the left anterior descending artery in the multivitamin group. These variables were not associated with the efficacy end points.

View this table: [in this window] [in a new window]   Table 1. Base-Line Demographic, Clinical, and Angiographic Characteristics of the Four Study Groups.

 
Eleven patients were randomly assigned to study groups but did not undergo angioplasty; seven were treated medically, three required bypass surgery, and one died before the scheduled date of angioplasty. Standard balloon angioplasty was successful in 81 to 84 percent of patients in each study group. There were 51 failures of angioplasty; 36 patients did not meet the angiographic criteria for successful angioplasty, 10 patients underwent stenting, 2 required urgent bypass surgery, and 3 had a Q-wave myocardial infarction within 24 hours after the procedure.

Twelve patients discharged after successful angioplasty did not undergo final arteriography. One of these patients died, three withdrew from the study, three underwent repeated angioplasty, three underwent surgical revascularization without meeting the quantitative criteria for restenosis at early angiography, one with myocardial infarction did not undergo follow-up angiography, and one was excluded because of inadequate angiographic data. Thirteen patients were not adequately compliant with the study regimen (three in the probucol group, three in the combined-treatment group, six in the multivitamin group, and one in the placebo group). The base-line characteristics examined in the 317 patients who underwent randomization were also evaluated in the 255 patients in the intention-to-treat analysis who had successful angioplasty and the 230 of these patients who completed the study without protocol violations. In these populations, the same differences among the groups were found.

Angiographic Analysis

Table 2 summarizes quantitative angiographic findings in the 230 patients who completed the study without protocol violations. The mean reduction in luminal diameter among the patients (the primary efficacy end point) was 0.12±0.41 mm in the probucol group, 0.22±0.46 mm in the combined-treatment group, 0.33±0.51 mm in the multivitamin group, and 0.38±0.50 mm in the placebo group (P = 0.006 for patients given probucol as compared with those not given probucol, and P = 0.70 for those given vitamins as compared with those not given vitamins). There was no evidence of significant interaction between probucol and multivitamins in the factorial design (P = 0.13). However, considering that the power of the study to detect such an interaction was 0.33, we performed a post hoc analysis comparing each two of the four groups separately, with adjustment for a possible interaction. The results remained significant for all angiographic end points in the comparison of the probucol and placebo groups. When the 13 noncompliant patients were added to the analysis, the mean reduction in luminal diameter was 0.13±0.41 mm for the probucol group, 0.23±0.45 mm for the combined-treatment group, 0.34±0.51 mm for the multivitamin group, and 0.39±0.51 mm for the placebo group (P = 0.003 for probucol vs. no probucol, and P = 0.65 for vitamins vs. no vitamins).

View this table: [in this window] [in a new window]   Table 2. Quantitative Angiographic Analysis of the 230 Patients Who Completed the Study without Protocol Violations.

 
Restenosis occurred in 20.7 percent of the dilated segments in the probucol group, 28.9 percent in the combined-treatment group, 40.3 percent in the multivitamin group, and 38.9 percent in the placebo group (P = 0.003 for probucol vs. no probucol, and P = 0.89 for vitamins vs. no vitamins). Rates of restenosis among the patients were 25.0 percent in the probucol group, 35.9 percent in the combined-treatment group, 42.2 percent in the multivitamin group, and 42.9 percent in the placebo group (P = 0.004 for probucol vs. no probucol, and P = 0.49 for vitamins vs. no vitamins). Figure 1 shows the cumulative-frequency curves for the minimal luminal diameter in all study groups.

View larger version (9K): [in this window] [in a new window]   Figure 1. Cumulative Distribution of the Minimal Luminal Diameter before Angioplasty, 15 Minutes after Angioplasty, and at Follow-up among Patients in the Four Study Groups Who Completed the Study without Protocol Violations. The curves clearly favor probucol at follow-up. PTCA denotes percutaneous transluminal coronary angioplasty.

 
Major Clinical End Points

The numbers of deaths, myocardial infarctions, and bypass operations were very small (Table 3). Rates of repeated angioplasty were 11.2 percent in the probucol group, 16.2 percent in the combined-treatment group, 24.4 percent in the multivitamin group, and 26.6 percent in the placebo group (P = 0.009 for probucol vs. no probucol, and P = 0.75 for vitamins vs. no vitamins).

View this table: [in this window] [in a new window]   Table 3. Major Clinical Events in the Four Study Groups.

 
Side Effects and Drug and Lipid Levels

Diarrhea was reported by 15.6 percent of the probucol group, 32.8 percent of the combined-treatment group, 7.8 percent of the multivitamin group, and 1.6 percent of the placebo group (P = 0.001). Yellow skin pigmentation was observed in 56 percent of all patients taking multivitamins.

Probucol and alpha-tocopherol levels had already reached plateaus at the time of angioplasty (Table 4). Total and low-density lipoprotein (LDL) cholesterol levels at follow-up were 9 percent and 3 percent lower, respectively, in the probucol group than in the placebo group. As expected, probucol also reduced high-density lipoprotein cholesterol levels by 41 percent.

View this table: [in this window] [in a new window]   Table 4. Lipid and Drug Levels in the Four Study Groups.

 
Discussion

To date, no pharmacologic approach has been conclusively shown to prevent coronary restenosis after balloon angioplasty. Four small studies suggested that probucol treatment, started before angioplasty, may prevent restenosis, but they were not double-blinded and two did not use quantitative angiographic methods.^6,7,8,9 The reported rate of restenosis was, nevertheless, as low as 8 percent when probucol was given from 30 days before angioplasty.⁶ Data from our study now provide strong evidence that probucol therapy initiated 30 days before angioplasty and given for 6 months thereafter prevents restenosis, as documented angiographically. As compared with placebo, probucol given alone resulted in decreases of 68 percent in late reductions in luminal diameter, 47 percent in the proportion of dilated coronary-artery segments with restenosis, and 58 percent in the need for repeated angioplasty. The importance of beginning therapy with probucol before angioplasty appears critical, considering the negative results of the Angioplasty plus Probucol/Lovastatin Evaluation, in which probucol and lovastatin treatment was started between 48 hours before and 24 hours after angioplasty.²¹ Data suggesting that probucol accumulates slowly in tissue²² probably explain these results.

Our study design included 30 days of pretreatment to ensure adequate control of the oxidative stress that occurs early after angioplasty. Damaged endothelium, activated platelets, and neutrophils at the angioplasty site can generate reactive intermediates.²³ These oxidizing metabolites can induce chain reactions that result in endothelial dysfunction²⁴ and oxidation of LDL.²⁵ Macrophages activated by oxidized LDL and dysfunctional endothelium can, in turn, release several growth factors that promote tissue proliferation. Extracellular changes also occur as metalloproteinases are secreted, accompanied by an increase in matrix synthesis.²⁶ Cross-linking of collagen could cause chronic vascular constriction.²⁷ Furthermore, endothelial dysfunction may hinder beneficial vascular remodeling by limiting flow-dependent changes in arterial dimensions.²⁸

The powerful antioxidant effects of probucol²⁹ may have prevented endothelial dysfunction³⁰ and LDL oxidation³¹ in our patients; this drug may also have modified neointimal formation and vascular remodeling, which are involved in the process of restenosis. Other mechanisms of action have to be considered, however, in view of the disappointing results of therapy with multivitamins in this study. The hypocholesterolemic effect of probucol is weak and is unlikely by itself to be responsible for the positive results, considering that high-dose lovastatin started 7 to 10 days before angioplasty failed to prevent restenosis in a recent trial.³² The role of probucol in reverse cholesterol transport and interleukin secretion, however, may have contributed to our good results. In particular, inhibition by probucol of the secretion of interleukin-1 by macrophages³³ may have decreased the secretion of metalloproteinases by smooth-muscle cells³⁴ and affected remodeling of the extracellular matrix. Whether probucol acted by preventing neointimal formation, improving arterial remodeling, or both, cannot be adequately addressed by angiography.

We also examined our patients with intravascular ultrasonography after angioplasty and at follow-up, with the angioplasty operators blinded to the results. The serial tomographic views of the arterial wall and lumen provided by ultrasound will enable us to determine the effects of probucol on remodeling and proliferation.

In contrast to probucol, multivitamins had no significant effect on the rate of angiographic restenosis or on major clinical end points. Vitamin E is a lipophilic antioxidant present in LDL³⁵ and cellular membranes.³⁶ A daily dose of 1400 IU was chosen on the basis of data showing higher serum levels at doses over 1000 IU daily.³⁷ We also administered an additional dose of 2000 IU of vitamin E 12 hours before angioplasty, because stable plasma levels of hydrogen peroxide were observed with such a regimen during bypass surgery.³⁸ We opted for a multivitamin complex because of the capacity of vitamin C to regenerate the antioxidant activity of vitamin E³⁹ and because beta carotene can modulate endothelial function and possibly interacts directly with nuclear receptors.⁴⁰

Considering that probucol and multivitamins are both antioxidants, it is not clear why multivitamins did not prevent restenosis but probucol did. Moderately intense dietary intervention was carried out with all patients and included limitation of vitamin intake, instructions to avoid vitamin and mineral supplements, and teaching of the Step 1 diet. Smoking habits, which may modify antioxidant requirements, were similar in all groups. Probucol may simply be a more powerful antioxidant than multivitamins. Alternatively, other properties may have contributed to this result. Indeed, the effects of probucol, vitamin E, and beta carotene on atherosclerosis⁴⁰ and vascular reactivity⁴¹ are not clearly related to their antioxidant properties in studies in animals. The possibility that the vitamins used in our patients, including the dose given 12 hours before angioplasty, paradoxically acted as prooxidants must also be considered.⁴² This phenomenon might also explain the tendency for probucol to have better results when given alone than when combined with multivitamins.

Finally, we focused on standard balloon angioplasty because of the different pathophysiology of restenosis in stented arteries. Interestingly, stents have been proved to reduce restenosis only in large arteries with short lesions, whereas there was no limitation on vessel size or the length of lesions in this trial.

Supported in part by grants from the Medical Research Council of Canada, Hoechst–Marion–Roussel, C.E. Jamieson, and the Fonds de Recherche de l'Institut de Cardiologie de Montréal.

We are indebted to Mrs. Viviane Douville for her expert secretarial work throughout the study.

^* Participants in the Multivitamins and Probucol (MVP) Study Group are listed in the Appendix.

Source Information

From the Department of Medicine, Montreal Heart Institute (J.-C.T., G.C., J. Lespérance, M.B., S.D., L.B., S.N., P.G.), and the University of Montreal (J. Lambert), Montreal. Presented in part at the 69th Scientific Sessions of the American Heart Association, New Orleans, November 11, 1996.

Address reprint requests to Dr. Côté at the Research Center, Montreal Heart Institute, 5000 Bélanger St., Montreal, QC H1T 1C8, Canada.

References

1. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med 1994;330:981-993. [Free Full Text]
2. Ferns GAA, Forster L, Stewart-Lee A, Konneh M, Nourooz-Zadeh J, Anggard EE. Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc Natl Acad Sci U S A 1992;89:11312-11316. [Free Full Text]
3. Schneider JE, Berk BC, Gravanis MB, et al. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury: a possible role for antioxidants in restenosis. Circulation 1993;88:628-637. [Free Full Text]
4. Freyschuss A, Stiko-Rahm A, Swedenborg J, et al. Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J Clin Invest 1993;91:1282-1288.
5. Nunes GL, Sgoutas DS, Redden RA, et al. Combination of vitamins C and E alters the response to coronary balloon injury in the pig. Arterioscler Thromb Vasc Biol 1995;15:156-165. [Free Full Text]
6. Lee YJ, Yamaguchi H, Daida H, et al. Pharmacological interventions to modify restenosis. Circulation 1991;84:Suppl II:II-299.abstract 
7. Setsuda M, Inden M, Hiraoka N, et al. Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Clin Ther 1993;15:374-382. [Medline]
8. Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996;132:23-29. [CrossRef][Medline]
9. Yokoi H, Yamaguchi H, Kuwabara Y. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty: Probucol Angioplasty Restenosis Trial (PART). J Am Coll Cardiol 1996;27:Suppl A:391A-391A.abstract 
10. DeMaio SJ, King SB III, Lembo NJ, et al. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA). J Am Coll Nutr 1992;11:68-73. [Abstract]
11. Burke BS. The dietary history as a tool in research. J Am Diet Assoc 1947;23:1041-1046. 
12. Health and Welfare Canada. Canadian nutrient file. Ottawa, Ont.: Supply and Services Canada, 1991.
13. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988;148:36-69. [Abstract]
14. Beaudry M, Galibois I, Chaumette P. Assessing the quality of food intake with the 1990 nutrition recommendations: four indicators proposed. J Can Diet Assoc 1996;57:7-11. 
15. Schäfer-Elinder L, Walldius G. Simultaneous measurement of serum probucol and lipid-soluble antioxidants. J Lipid Res 1992;33:131-137. [Abstract]
16. Reiber JHC, van der Zwet PMJ, von Land CD, et al. Quantitative coronary arteriography: equipment and technical requirements. In: Reiber JHC, Serruys PW, eds. Advances in quantitative coronary arteriography. Vol. 137 of Developments in cardiovascular medicine. Dordrecht, the Netherlands: Kluwer Academic, 1993:75-111.
17. Lespérance J, Waters D. Measuring progression and regression of coronary atherosclerosis in clinical trials: problems and progress. Int J Card Imaging 1992;8:165-173. [CrossRef][Medline]
18. Schwartz L, Bourassa MG, Lespérance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719. [Abstract]
19. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22. [Free Full Text]
20. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977;64:191-199. [Free Full Text]
21. O'Keefe JH Jr, Stone GW, McCallister BD Jr, et al. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1996;77:649-652. [CrossRef][Medline]
22. Reaven PD, Parthasarathy S, Beltz WF, Witztum JL. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler Thromb 1992;12:318-324. [Free Full Text]
23. Southorn PA, Powis G. Free radicals in medicine. I. Chemical nature and biologic reactions. Mayo Clin Proc 1988;63:381-389. [Medline]
24. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344:160-162. [CrossRef][Medline]
25. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924. [Medline]
26. Strauss BH, Chisholm RJ, Keeley FW, Gotlieb AI, Logan RA, Armstrong PW. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res 1994;75:650-658. [Free Full Text]
27. Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol 1995;25:516-520. [Abstract]
28. Langille BL, O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science 1986;231:405-407. [Free Full Text]
29. Steinberg D. Studies on the mechanism of action of probucol. Am J Cardiol 1986;57:16H-21H. [CrossRef][Medline]
30. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493. [Free Full Text]
31. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986;77:641-644.
32. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331-1337. [Free Full Text]
33. Ku G, Doherty NS, Wolos JA, Jackson RL. Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis. Am J Cardiol 1988;62:77B-81B. [CrossRef][Medline]
34. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994;75:181-189. [Free Full Text]
35. Jialal I, Grundy SM. Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low density lipoprotein. J Lipid Res 1992;33:899-906. [Abstract]
36. Burton GW, Ingold KU. Vitamin E as an in vitro and in vivo antioxidant. Ann N Y Acad Sci 1989;570:7-22. [Abstract]
37. Brin MF, Fahn S, Loftus S, McMahon D, Flaster E. Relationship between dose of vitamin E administered and blood level. Ann N Y Acad Sci 1989;570:421-424. 
38. Cavarocchi NC, England MD, O'Brien JF, et al. Superoxide generation during cardiopulmonary bypass: is there a role for vitamin E? J Surg Res 1986;40:519-527. [CrossRef][Medline]
39. Kagan VE, Serbinova EA, Forte T, Scita G, Packer L. Recycling of vitamin E in human low density lipoproteins. J Lipid Res 1992;33:385-397. [Abstract]
40. Shaish A, Daugherty A, O'Sullivan F, Schonfeld G, Heinecke JW. Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J Clin Invest 1995;96:2075-2082.
41. Keaney JF Jr, Gaziano JM, Xu A, et al. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc Natl Acad Sci U S A 1993;90:11880-11884. [Free Full Text]
42. Burton GW, Ingold KU. -Carotene: an unusual type of lipid antioxidant. Science 1984;224:569-573. [Free Full Text]

The following participated in the MVP study: Associate Investigators — D. Bois, R. Bonan, J. Crépeau, M. DeBelder, R. Gallo, D. Gossard, G. Gosselin, M. Joyal, M. Juneau, M. Naruszewich, and J.-F. Tanguay; Quantitative Coronary Angiography Laboratory — F. Bélanger, M.-J. Dussault, and C. Desjardins; Data Coordination — L. Blain, S. Bujold, M. Caron, J. Chaput, D. Larocque, and A.-M. Poitras; Data Entry and Analysis — R. Aubut, C. Dupont, F. Harel, and J. Perrault; Study Monitoring — E.L. Alderman, K.M. Detre, D. Faxon (chairman), and A. Rosen.

Abstract PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Related Letters:

Probucol and Multivitamins in the Prevention of Restenosis after Coronary Angioplasty
Sirtori C. R., Franceschini G., Jay S. J., Lisi D. M., Côté G., Tardif J. C., Lespérance J.
Extract | Full Text  
N Engl J Med 1997; 337:1918-1919, Dec 25, 1997. Correspondence

This article has been cited by other articles:

• Levonen, A.-L., Vahakangas, E., Koponen, J. K., Yla-Herttuala, S. (2008). Antioxidant Gene Therapy for Cardiovascular Disease: Current Status and Future Perspectives. Circulation 117: 2142-2150 [Abstract] [Full Text]  
• Siekmeier, R., Steffen, C., Marz, W. (2007). Role of Oxidants and Antioxidants in Atherosclerosis: Results of In Vitro and In Vivo Investigations. J CARDIOVASC PHARMACOL THER 12: 265-282 [Abstract]  
• Korshunov, V. A., Schwartz, S. M., Berk, B. C. (2007). Vascular Remodeling: Hemodynamic and Biochemical Mechanisms Underlying Glagov's Phenomenon. Arterioscler. Thromb. Vasc. Bio. 27: 1722-1728 [Abstract] [Full Text]  
• Jiang, W.-J., Xu, X.-T., Jin, M., Du, B., Dong, K.-H., Dai, J.-P. (2007). Apollo Stent for Symptomatic Atherosclerotic Intracranial Stenosis: Study Results. Am. J. Neuroradiol. 28: 830-834 [Abstract] [Full Text]  
• Wierzbicki, A. S (2007). Voodoo medicine -- cardiovascular trials jinxed in New Orleans: Dr Anthony Wierzbicki discusses highlights of the 56th Annual Scientific Session of American College of Cardiology held at Morial Conventions Centre in New Orleans March 24th--27th, 2007. British Journal of Diabetes & Vascular Disease 7: 142-144  
• Tardif, J.-C., Gregoire, J., L'Allier, P. L., Ibrahim, R., Lesperance, J., Heinonen, T. M., Kouz, S., Berry, C., Basser, R., Lavoie, M.-A., Guertin, M.-C., Rodes-Cabau, J., for the Effect of rHDL on Atherosclerosis-Safety a, (2007). Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis: A Randomized Controlled Trial. JAMA 297: 1675-1682 [Abstract] [Full Text]  
• Stocker, R., Perrella, M. A. (2006). Heme Oxygenase-1: A Novel Drug Target for Atherosclerotic Diseases?. Circulation 114: 2178-2189 [Full Text]  
• Bleys, J., Miller, E. R III, Pastor-Barriuso, R., Appel, L. J, Guallar, E. (2006). Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials.. Am. J. Clin. Nutr. 84: 880-887 [Abstract] [Full Text]  
• Feletou, M., Vanhoutte, P. M. (2006). Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am. J. Physiol. Heart Circ. Physiol. 291: H985-H1002 [Abstract] [Full Text]  
• Fisher, M., Lees, K., Spence, J. D. (2006). Nutrition and Stroke Prevention. Stroke 37: 2430-2435 [Abstract] [Full Text]  
• Heinecke, J. W. (2006). Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander?. J. Exp. Med. 203: 813-816 [Abstract] [Full Text]  
• Wu, B. J., Kathir, K., Witting, P. K., Beck, K., Choy, K., Li, C., Croft, K. D., Mori, T. A., Tanous, D., Adams, M. R., Lau, A. K., Stocker, R. (2006). Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J. Exp. Med. 203: 1117-1127 [Abstract] [Full Text]  
• Franks, A. M, Gardner, S. F (2006). AGI-1067: A Novel Vascular Protectant for Prevention of Restenosis. The Annals of Pharmacotherapy 40: 66-73 [Abstract] [Full Text]  
• Hinagata, J.-i., Kakutani, M., Fujii, T., Naruko, T., Inoue, N., Fujita, Y., Mehta, J. L., Ueda, M., Sawamura, T. (2006). Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model. Cardiovasc Res 69: 263-271 [Abstract] [Full Text]  
• Koh, K. K., Han, S. H., Shin, M.-S., Ahn, J. Y., Lee, Y., Shin, E. K. (2005). Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. Eur Heart J 26: 1362-1368 [Abstract] [Full Text]  
• Goligorsky, M. S. (2005). Endothelial cell dysfunction: can't live with it, how to live without it. Am. J. Physiol. Renal Physiol. 288: F871-F880 [Abstract] [Full Text]  
• Witting, P. K., Wu, B. J., Raftery, M., Southwell-Keely, P., Stocker, R. (2005). Probucol Protects against Hypochlorite-induced Endothelial Dysfunction: IDENTIFICATION OF A NOVEL PATHWAY OF PROBUCOL OXIDATION TO A BIOLOGICALLY ACTIVE INTERMEDIATE. J. Biol. Chem. 280: 15612-15618 [Abstract] [Full Text]  
• Chen, J.-W., Lin, F.-Y., Chen, Y.-H., Wu, T.-C., Chen, Y.-L., Lin, S.-J. (2004). Carvedilol Inhibits Tumor Necrosis Factor-{alpha}-Induced Endothelial Transcription Factor Activation, Adhesion Molecule Expression, and Adhesiveness to Human Mononuclear Cells. Arterioscler. Thromb. Vasc. Bio. 24: 2075-2081 [Abstract] [Full Text]  
• Stocker, R., Keaney, J. F. Jr. (2004). Role of Oxidative Modifications in Atherosclerosis. Physiol. Rev. 84: 1381-1478 [Abstract] [Full Text]  
• Deng, Y.-M., Wu, B. J., Witting, P. K., Stocker, R. (2004). Probucol Protects Against Smooth Muscle Cell Proliferation by Upregulating Heme Oxygenase-1. Circulation 110: 1855-1860 [Abstract] [Full Text]  
• Chen, Z., Keaney, J. F. Jr., Schulz, E., Levison, B., Shan, L., Sakuma, M., Zhang, X., Shi, C., Hazen, S. L., Simon, D. I. (2004). Decreased neointimal formation in Nox2-deficient mice reveals a direct role for NADPH oxidase in the response to arterial injury. Proc. Natl. Acad. Sci. USA 101: 13014-13019 [Abstract] [Full Text]  
• Davignon, J., Ganz, P. (2004). Role of Endothelial Dysfunction in Atherosclerosis. Circulation 109: III-27-III-32 [Abstract] [Full Text]  
• Chyu, K.-Y., Babbidge, S. M., Zhao, X., Dandillaya, R., Rietveld, A. G., Yano, J., Dimayuga, P., Cercek, B., Shah, P. K. (2004). Differential Effects of Green Tea-Derived Catechin on Developing Versus Established Atherosclerosis in Apolipoprotein E-Null Mice. Circulation 109: 2448-2453 [Abstract] [Full Text]  
• Do, Y. S., Kao, E. Y., Ganaha, F., Minamiguchi, H., Sugimoto, K., Lee, J., Elkins, C. J., Amabile, P. G., Kuo, M. D., Wang, D. S., Waugh, J. M., Dake, M. D. (2004). In-Stent Restenosis Limitation with Stent-based Controlled-Release Nitric Oxide: Initial Results in Rabbits. Radiology 230: 377-382 [Abstract] [Full Text]  
• Leite, P. F., Danilovic, A., Moriel, P., Dantas, K., Marklund, S., Dantas, A. P. V., Laurindo, F. R.M. (2003). Sustained Decrease in Superoxide Dismutase Activity Underlies Constrictive Remodeling After Balloon Injury in Rabbits. Arterioscler. Thromb. Vasc. Bio. 23: 2197-2202 [Abstract] [Full Text]  
• Koh, K. K., Ahn, J. Y., Jin, D. K., Yoon, B.-K., Kim, H. S., Kim, D. S., Kang, W. C., Han, S. H., Choi, I. S., Shin, E. K. (2003). Significant Differential Effects of Hormone Therapy or Tibolone on Markers of Cardiovascular Disease in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Arterioscler. Thromb. Vasc. Bio. 23: 1889-1894 [Abstract] [Full Text]  
• Dee, S. V., Samady, H. (2003). Evolving Strategies for the Prevention and Treatment of Coronary Restenosis. SEMIN CARDIOTHORAC VASC ANESTH 7: 281-293 [Abstract]  
• Cipollone, F, Fazia, M, Iezzi, A, Pini, B, Costantini, F, De Cesare, D, Paloscia, L, Materazzo, G, D'Annunzio, E, Bucciarelli, T, Vecchiet, J, Chiarelli, F, Cuccurullo, F, Mezzetti, A (2003). High preprocedural non-HDL cholesterol is associated with enhanced oxidative stress and monocyte activation after coronary angioplasty: possible implications in restenosis. Heart 89: 773-779 [Abstract] [Full Text]  
• Morris, C. D., Carson, S. (2003). Routine Vitamin Supplementation To Prevent Cardiovascular Disease: A Summary of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 139: 56-70 [Abstract] [Full Text]  
• Braun, A., Zhang, S., Miettinen, H. E., Ebrahim, S., Holm, T. M., Vasile, E., Post, M. J., Yoerger, D. M., Picard, M. H., Krieger, J. L., Andrews, N. C., Simons, M., Krieger, M. (2003). Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc. Natl. Acad. Sci. USA 100: 7283-7288 [Abstract] [Full Text]  
• Lau, A. K., Leichtweis, S. B., Hume, P., Mashima, R., Hou, J. Y., Chaufour, X., Wilkinson, B., Hunt, N. H., Celermajer, D. S., Stocker, R. (2003). Probucol Promotes Functional Reendothelialization in Balloon-Injured Rabbit Aortas. Circulation 107: 2031-2036 [Abstract] [Full Text]  
• Gotto, A. M. Jr (2003). Antioxidants, statins, and atherosclerosis. J Am Coll Cardiol 41: 1205-1210 [Abstract] [Full Text]  
• Urban, P., Serruys, P., Baumgart, D., Colombo, A., Silber, S., Eeckhout, E., Gershlick, A., Wegscheider, K., Verhees, L., Bonan, R., For the RENO investigators, (2003). A multicentre European registry of intraluminal coronary beta brachytherapy. Eur Heart J 24: 604-612 [Abstract] [Full Text]  
• Tardif, J.-C., Gregoire, J., Schwartz, L., Title, L., Laramee, L., Reeves, F., Lesperance, J., Bourassa, M. G., L'Allier, P. L., Glass, M., Lambert, J., Guertin, M.-C., for the Canadian Antioxidant Restenosis Trial (CAR, (2003). Effects of AGI-1067 and Probucol After Percutaneous Coronary Interventions. Circulation 107: 552-558 [Abstract] [Full Text]  
• Waters, D. D., Alderman, E. L., Hsia, J., Howard, B. V., Cobb, F. R., Rogers, W. J., Ouyang, P., Thompson, P., Tardif, J. C., Higginson, L., Bittner, V., Steffes, M., Gordon, D. J., Proschan, M., Younes, N., Verter, J. I. (2002). Effects of Hormone Replacement Therapy and Antioxidant Vitamin Supplements on Coronary Atherosclerosis in Postmenopausal Women: A Randomized Controlled Trial. JAMA 288: 2432-2440 [Abstract] [Full Text]  
• Fontana, L., Giagulli, C., Cominacini, L., Pasini, A. F., Minuz, P., Lechi, A., Sala, A., Laudanna, C. (2002). {beta}2 Integrin-Dependent Neutrophil Adhesion Induced by Minimally Modified Low-Density Lipoproteins Is Mainly Mediated by F2-Isoprostanes. Circulation 106: 2434-2441 [Abstract] [Full Text]  
• Laukkanen, M. O., Kivela, A., Rissanen, T., Rutanen, J., Karkkainen, M. K., Leppanen, O., Brasen, J. H., Yla-Herttuala, S. (2002). Adenovirus-Mediated Extracellular Superoxide Dismutase Gene Therapy Reduces Neointima Formation in Balloon-Denuded Rabbit Aorta. Circulation 106: 1999-2003 [Abstract] [Full Text]  
• Komai, N., Morishita, R., Yamada, S., Oishi, M., Iguchi, S., Aoki, M., Sasaki, M., Sakurabayashi, I., Higaki, J., Ogihara, T. (2002). Mitogenic Activity of Oxidized Lipoprotein (a) on Human Vascular Smooth Muscle Cells. Hypertension 40: 310-314 [Abstract] [Full Text]  
• Theilmeier, G., Quarck, R., Verhamme, P., Bochaton-Piallat, M.-L., Lox, M., Bernar, H., Janssens, S., Kockx, M., Gabbiani, G., Collen, D., Holvoet, P. (2002). Hypercholesterolemia impairs vascular remodelling after porcine coronary angioplasty. Cardiovasc Res 55: 385-395 [Abstract] [Full Text]  
• Fairfield, K. M., Fletcher, R. H. (2002). Vitamins for Chronic Disease Prevention in Adults: Scientific Review. JAMA 287: 3116-3126 [Abstract] [Full Text]  
• Mori, E., Komori, K., Yamaoka, T., Tanii, M., Kataoka, C., Takeshita, A., Usui, M., Egashira, K., Sugimachi, K. (2002). Essential Role of Monocyte Chemoattractant Protein-1 in Development of Restenotic Changes (Neointimal Hyperplasia and Constrictive Remodeling) After Balloon Angioplasty in Hypercholesterolemic Rabbits. Circulation 105: 2905-2910 [Abstract] [Full Text]  
• Schnyder, G., Roffi, M., Flammer, Y., Pin, R., Hess, O.M. (2002). Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J 23: 726-733 [Abstract] [Full Text]  
• Pataki, T., Bak, I., Kovacs, P., Bagchi, D., Das, D. K, Tosaki, A. (2002). Grape seed proanthocyanidins improved cardiac recovery during reperfusion after ischemia in isolated rat hearts. Am. J. Clin. Nutr. 75: 894-899 [Abstract] [Full Text]  
• Violi, F., Micheletta, F., Iuliano, L. (2002). Antioxidants and atherosclerosis. Eur Heart J Suppl 4: B17-B21 [Abstract]  
• Sawayama, Y., Shimizu, C., Maeda, N., Tatsukawa, M., Kinukawa, N., Koyanagi, S., Kashiwagi, S., Hayashi, J. (2002). Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka atherosclerosis trial (FAST). J Am Coll Cardiol 39: 610-616 [Abstract] [Full Text]  
• Lowe, H. C., Oesterle, S. N., Khachigian, L. M. (2002). Coronary in-stent restenosis: Current status and future strategies. J Am Coll Cardiol 39: 183-193 [Abstract] [Full Text]  
• Park, K. S., Kim, J. H., Kim, M. S., Kim, J. M., Kim, S. K., Choi, J. Y., Chung, M. H., Han, B., Kim, S. Y., Lee, H. K. (2001). Effects of Insulin and Antioxidant on Plasma 8-Hydroxyguanine and Tissue 8-Hydroxydeoxyguanosine in Streptozotocin-Induced Diabetic Rats. Diabetes 50: 2837-2841 [Abstract] [Full Text]  
• Schnyder, G., Roffi, M., Pin, R., Flammer, Y., Lange, H., Eberli, F. R., Meier, B., Turi, Z. G., Hess, O. M. (2001). Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels. NEJM 345: 1593-1600 [Abstract] [Full Text]  
• Brasen, J. H., Kivela, A., Roser, K., Rissanen, T. T., Niemi, M., Luft, F. C., Donath, K., Yla-Herttuala, S. (2001). Angiogenesis, Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor-BB Expression, Iron Deposition, and Oxidation-Specific Epitopes in Stented Human Coronary Arteries. Arterioscler. Thromb. Vasc. Bio. 21: 1720-1726 [Abstract] [Full Text]  
• Pettersen, R. J., Muna, Z. A., Kuiper, K. K.J., Svendsen, E., Muller, F., Aukrust, P., Berge, R. K., Erik Nordrehaug, J. (2001). Sustained retention of tetradecylthioacetic acid after local delivery reduces angioplasty-induced coronary stenosis in the minipig. Cardiovasc Res 52: 306-313 [Abstract] [Full Text]  
• Rosenthal, E. A., Bohlmeyer, T. J., Monnet, E., MacPhail, C., Robertson, A. D., Horwitz, M. A., Burchenal, J. E.B., Horwitz, L. D. (2001). An Iron-Binding Exochelin Prevents Restenosis Due to Coronary Artery Balloon Injury in a Porcine Model. Circulation 104: 2222-2227 [Abstract] [Full Text]  
• Nakayama, M., Takahashi, K., Komaru, T., Fukuchi, M., Shioiri, H., Sato, K.-i., Kitamuro, T., Shirato, K., Yamaguchi, T., Suematsu, M., Shibahara, S. (2001). Increased Expression of Heme Oxygenase-1 and Bilirubin Accumulation in Foam Cells of Rabbit Atherosclerotic Lesions. Arterioscler. Thromb. Vasc. Bio. 21: 1373-1377 [Abstract] [Full Text]  
• Ward, M. R., Kanellakis, P., Ramsey, D., Funder, J., Bobik, A. (2001). Eplerenone Suppresses Constrictive Remodeling and Collagen Accumulation After Angioplasty in Porcine Coronary Arteries. Circulation 104: 467-472 [Abstract] [Full Text]  
• Aoki, M., Nata, T., Morishita, R., Matsushita, H., Nakagami, H., Yamamoto, K., Yamazaki, K., Nakabayashi, M., Ogihara, T., Kaneda, Y. (2001). Endothelial Apoptosis Induced by Oxidative Stress Through Activation of NF-{kappa}B: Antiapoptotic Effect of Antioxidant Agents on Endothelial Cells. Hypertension 38: 48-55 [Abstract] [Full Text]  
• Smith, S. C. Jr, Dove, J. T., Jacobs, A. K., Ward Kennedy, J., Kereiakes, D., Kern, M. J., Kuntz, R. E., Popma, J. J., Schaff, H. V., Williams, D. O., Gibbons, R. J., Alpert, J. P., Eagle, K. A., Faxon, D. P., Fuster, V., Gardner, T. J., Gregoratos, G., Russell, R. O., Smith, S. C. Jr (2001). ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 37: 2239-2239 [Full Text]  
• Shi, Y., Niculescu, R., Wang, D., Patel, S., Davenpeck, K. L., Zalewski, A. (2001). Increased NAD(P)H Oxidase and Reactive Oxygen Species in Coronary Arteries After Balloon Injury. Arterioscler. Thromb. Vasc. Bio. 21: 739-745 [Abstract] [Full Text]  
• Tomimoto, S., Tsujita, M., Okazaki, M., Usui, S., Tada, T., Fukutomi, T., Ito, S., Itoh, M., Yokoyama, S. (2001). Effect of Probucol in Lecithin-Cholesterol Acyltransferase-Deficient Mice : Inhibition of 2 Independent Cellular Cholesterol-Releasing Pathways In Vivo. Arterioscler. Thromb. Vasc. Bio. 21: 394-400 [Abstract] [Full Text]  
• Tardif, J.-C., Gregoire, J., Serruys, P. W., Foley, D. P., Hofling, B., Puel, J., Glogar, H. D., Seabra-Gomes, R., Goicolea, J., Coste, P., Rutsch, W., Katus, H., Bonnier, H., Wijns, W., Betriu, A., Hauf-Zachariou, U., Montauban van Swijndregt, E., Melkert, R., Simon, R. (2001). Antioxidants and Prevention of Restenosis After Directional Coronary Atherectomy Response. Circulation 103 : e51-e52 [Full Text]  
• Fontana, L., Giagulli, C., Minuz, P., Lechi, A., Laudanna, C. (2001). 8-Iso-PGF2{{alpha}} Induces {beta}2-Integrin-Mediated Rapid Adhesion of Human Polymorphonuclear Neutrophils : A Link Between Oxidative Stress and Ischemia/Reperfusion Injury. Arterioscler. Thromb. Vasc. Bio. 21: 55-60 [Abstract] [Full Text]  
• Chai, Y.-C., Binion, D. G., Chisolm, G. M. (2000). Relationship of molecular structure to the mechanism of lysophospholipid-induced smooth muscle cell proliferation. Am. J. Physiol. Heart Circ. Physiol. 279: H1830-H1838 [Abstract] [Full Text]  
• Jianhua Zhu, , Danchen Gao, (2000). Losartan reduces collagen content and intimal thickening of iliac arteries after balloon injury in rabbits. Journal of Renin-Angiotensin-Aldosterone System 1: 278-282 [Abstract]  
• Azevedo, L. C.P., Pedro, M. d. A., Souza, L. C., de Souza, H. P., Janiszewski, M., da Luz, P. L., Laurindo, F. R.M. (2000). Oxidative stress as a signaling mechanism of the vascular response to injury: The redox hypothesis of restenosis. Cardiovasc Res 47: 436-445 [Abstract] [Full Text]  
• Altavilla, D., Deodato, B., Campo, G. M., Arlotta, M., Miano, M., Squadrito, G., Saitta, A., Cucinotta, D., Ceccarelli, S., Ferlito, M., Tringali, M., Minutoli, L., Caputi, A. P., Squadrito, F. (2000). IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-{kappa}B and reduces the inflammatory response in myocardial ischemia-reperfusion injury. Cardiovasc Res 47: 515-528 [Abstract] [Full Text]  
• Witting, P. K., Pettersson, K., Letters, J., Stocker, R. (2000). Site-Specific Antiatherogenic Effect of Probucol in Apolipoprotein E-Deficient Mice. Arterioscler. Thromb. Vasc. Bio. 20 : e26-e33 [Abstract] [Full Text]  
• Waugh, J. M., Li-Hawkins, J., Yuksel, E., Kuo, M. D., Cifra, P. N., Hilfiker, P. R., Geske, R., Chawla, M., Thomas, J., Shenaq, S. M., Dake, M. D., Woo, S. L. C. (2000). Thrombomodulin Overexpression to Limit Neointima Formation. Circulation 102: 332-337 [Abstract] [Full Text]  
• Meerkin, D., Tardif, J.-C., Bertrand, O. F., Vincent, J., Harel, F., Bonan, R. (2000). The effects of intracoronary brachytherapy on the natural history of postangioplasty dissections. J Am Coll Cardiol 36: 59-64 [Abstract] [Full Text]  
• Serruys, P. W., Foley, D. P., Hofling, B., Puel, J., Glogar, H. D., Seabra-Gomes, R., Goicolea, J., Coste, P., Rutsch, W., Katus, H., Bonnier, H., Wijns, W., Betriu, A., Hauf-Zachariou, U., van Swijndregt, E. M., Melkert, R., Simon, R. (2000). Carvedilol for Prevention of Restenosis After Directional Coronary Atherectomy : Final Results of the European Carvedilol Atherectomy Restenosis (EUROCARE) Trial. Circulation 101: 1512-1518 [Abstract] [Full Text]  
• Connors III, J. J., Seidenwurm, D., Wojak, J. C., Hurst, R. W., Jensen, M. E., Wallace, R., Tomsick, T., Barr, J., Kerber, C., Russell, E., Nesbit, G. M., Fox, A. J., Tsai, F. Y. (2000). Treatment of Atherosclerotic Disease at the Cervical Carotid Bifurcation: Current Status and Review of the Literature. Am. J. Neuroradiol. 21: 444-450 [Full Text]  
• Schroepfer, G. J. Jr. (2000). Oxysterols: Modulators of Cholesterol Metabolism and Other Processes. Physiol. Rev. 80: 361-554 [Abstract] [Full Text]  
• Feng, A.-N., Chen, Y.-L., Chen, Y.-T., Ding, Y.-Z., Lin, S.-J. (1999). Red Wine Inhibits Monocyte Chemotactic Protein-1 Expression and Modestly Reduces Neointimal Hyperplasia After Balloon Injury in Cholesterol-Fed Rabbits. Circulation 100: 2254-2259 [Abstract] [Full Text]  
• Mezzetti, A., Guglielmi, M. D., Pierdomenico, S. D., Costantini, F., Cipollone, F., De Cesare, D., Bucciarelli, T., Ucchino, S., Chiarelli, F., Cuccurullo, F., Romano, F. (1999). Increased Systemic Oxidative Stress After Elective Endarterectomy : Relation to Vascular Healing and Remodeling. Arterioscler. Thromb. Vasc. Bio. 19: 2659-2665 [Abstract] [Full Text]  
• Eagle, K. A., Guyton, R. A., Davidoff, R., Ewy, G. A., Fonger, J., Gardner, T. J., Gott, J. P., Herrmann, H. C., Marlow, R. A., Nugent, W. C., O'Connor, G. T., Orszulak, T. A., Rieselbach, R. E., Winters, W. L., Yusuf, S., Gibbons, R. J., Alpert, J. S., Eagle, K. A., Gardner, T. J., Garson, A. Jr., Gregoratos, G., Russell, R. O., Smith, S. C. Jr. (1999). ACC/AHA guidelines for coronary artery bypass graft surgery: A report of the American College of Cardiology/ American Heart Association task force on Practice Guidelines (Committee to revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 34: 1262-1347 [Full Text]  
• Hollis, S., Campbell, F. (1999). What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319: 670-674 [Abstract] [Full Text]  
• Harjai, K. J. (1999). Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen. ANN INTERN MED 131: 376-386 [Abstract] [Full Text]  
• Yusuf, S. (1999). Randomised controlled trials in cardiovascular medicine: past achievements, future challenges. BMJ 319: 564-568 [Full Text]  
• Brar, S. S., Kennedy, T. P., Whorton, A. R., Murphy, T. M., Chitano, P., Hoidal, J. R. (1999). Requirement for Reactive Oxygen Species in Serum-induced and Platelet-derived Growth Factor-induced Growth of Airway Smooth Muscle. J. Biol. Chem. 274: 20017-20026 [Abstract] [Full Text]  
• Bilder, G., Wentz, T., Leadley, R., Amin, D., Byan, L., O'Conner, B., Needle, S., Galczenski, H., Bostwick, J., Kasiewski, C., Myers, M., Spada, A., Merkel, L., Ly, C., Persons, P., Page, K., Perrone, M., Dunwiddie, C. (1999). Restenosis Following Angioplasty in the Swine Coronary Artery Is Inhibited By an Orally Active PDGF-Receptor Tyrosine Kinase Inhibitor, RPR101511A. Circulation 99: 3292-3299 [Abstract] [Full Text]  
• Johansen, O., Brekke, M., Seljeflot, I., Abdelnoor, M., Arnesen, H. (1999). n-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. J Am Coll Cardiol 33: 1619-1626 [Abstract] [Full Text]  
• Rinninger, F., Wang, N., Ramakrishnan, R., Jiang, X. C., Tall, A. R. (1999). Probucol Enhances Selective Uptake of HDL-Associated Cholesteryl Esters In Vitro by a Scavenger Receptor B-I–Dependent Mechanism. Arterioscler. Thromb. Vasc. Bio. 19: 1325-1332 [Abstract] [Full Text]  
• Moghadasian, M. H., McManus, B. M., Godin, D. V., Rodrigues, B., Frohlich, J. J. (1999). Proatherogenic and Antiatherogenic Effects of Probucol and Phytosterols in Apolipoprotein E–Deficient Mice : Possible Mechanisms of Action. Circulation 99: 1733-1739 [Abstract] [Full Text]  
• Tribble, D. L. (1999). Antioxidant Consumption and Risk of Coronary Heart Disease: Emphasis on Vitamin C, Vitamin E, and ß-Carotene : A Statement for Healthcare Professionals From the American Heart Association. Circulation 99: 591-595 [Full Text]  
• Pollman, M. J., Hall, J. L., Gibbons, G. H. (1999). Determinants of Vascular Smooth Muscle Cell Apoptosis After Balloon Angioplasty Injury : Influence of Redox State and Cell Phenotype. Circ. Res. 84: 113-121 [Abstract] [Full Text]  
• Cote, G., Tardif, J.-C., Lesperance, J., Lambert, J., Bourassa, M., Bonan, R., Gosselin, G., Joyal, M., Tanguay, J.-F., Nattel, S., Gallo, R., Crepeau, J. (1999). Effects of Probucol on Vascular Remodeling After Coronary Angioplasty. Circulation 99: 30-35 [Abstract] [Full Text]  
• Klugherz, B. D., Meneveau, N., Chen, W., Wade-Whittaker, F., Papandreou, G., Levy, R., Wilensky, R. L. (1999). Sustained Intramural Retention and Regional Redistribution Following Local Vascular Delivery of Polylactic-Coglycolic Acid and Liposomal Nanoparticulate Formulations Containing Probucol. J CARDIOVASC PHARMACOL THER 4: 167-174 [Abstract]  
• Heckenkamp, J., Lamuraglia, G. M. (1999). Intimal Hyperplasia, Arterial Remodeling, and Restenosis: An Overview. PERSPECT VASC SURG ENDOVASC THER 11: 71-94 [Abstract]  
• Loop, F. D. (1998). Coronary artery surgery: the end of the beginning. Eur. J. Cardiothorac. Surg. 14: 554-571 [Abstract] [Full Text]  
• Tröger, U., Meyer, F. P (1998). Personal paper: Validity of advertising claims for multivitamin preparation Vitacor 20/90 on the internet. BMJ 317: 1069-1071 [Full Text]  
• Janiszewski, M., Pasqualucci, C. A, Souza, L. C, Pileggi, F., da Luz, P. L, M. Laurindo, F. R (1998). Oxidized thiols markedly amplify the vascular response to balloon injury in rabbits through a redox active metal-dependent pathway. Cardiovasc Res 39: 327-338 [Abstract] [Full Text]  
• Speir, E., Yu, Z.-X., Ferrans, V. J., Huang, E.-S., Epstein, S. E. (1998). Aspirin Attenuates Cytomegalovirus Infectivity and Gene Expression Mediated by Cyclooxygenase-2 in Coronary Artery Smooth Muscle Cells. Circ. Res. 83: 210-216 [Abstract] [Full Text]  
• Lafont, A., Faxon, D. (1998). Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials?. Cardiovasc Res 39: 50-59 [Full Text]  
• DeYoung, M. B., Dichek, D. A. (1998). Gene Therapy for Restenosis : Are We Ready?. Circ. Res. 82: 306-313 [Abstract] [Full Text]  
• Edelman, E. R. (1998). Vessel Size, Antioxidants, and Restenosis : Never Too Small, Not Too Little, but Often Too Late. Circulation 97: 416-420 [Full Text]  
• Rodes, J., Cote, G., Lesperance, J., Bourassa, M. G., Doucet, S., Bilodeau, L., Bertrand, O. F., Harel, F., Gallo, R., Tardif, J.-C. (1998). Prevention of Restenosis After Angioplasty in Small Coronary Arteries With Probucol. Circulation 97: 429-436 [Abstract] [Full Text]  
• Sirtori, C. R., Franceschini, G., Jay, S. J., Lisi, D. M., Cote, G., Tardif, J. C., Lesperance, J. (1997). Probucol and Multivitamins in the Prevention of Restenosis after Coronary Angioplasty. NEJM 337: 1918-1919 [Full Text]  
• Braunwald, E. (1997). Cardiovascular Medicine at the Turn of the Millennium: Triumphs, Concerns, and Opportunities. NEJM 337: 1360-1369 [Full Text]  
• (1997). Probucol Prevents Restenosis. Journal Watch Cardiology 1997: 2-2 [Full Text]